Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis

Authors

Institutions

Publication Details

Journal
The Lancet Oncology
Published
2024-12-01
DOI
https://doi.org/10.1016/s1470-2045(24)00505-9
Citations
6
Primary Topic
Economic and Financial Impacts of Cancer
Type
article
Field-Weighted Citation Impact
6.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis

Aris Angelis, Panos G. Kanavos, Erica Visintin
6 citations
The Lancet Oncology
Economic and Financial Impacts of Cancer
6.78
article

Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis

Aris Angelis, Panos G. Kanavos, Erica Visintin
article en
6 citations

Abstract

No abstract available for this paper.
The Lancet OncologyVol. 25(12)
London School of Economics and Political Science (GB)
Openalex Percentile: Top 3%
Economic and Financial Impacts of Cancer
6.78
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.